[Yao Qiankun] the team of "Tu youyou" swipe the screen! Artemisinin concept shares rose, Fosun, kunyao, Haizheng Pharmaceutical

Yesterday, according to Xinhua In view of the problem of artemisinin resistance in some parts of the world in recent years, Tu youyou and her team have made new breakthroughs in "malaria resistance mechanism research", "drug resistance causes", "adjustment of treatment methods" and other aspects after years of hard work In the near future, they have put forward a practical treatment plan to deal with the problem of artemisinin resistance, and in "artemisinin treatment of lupus erythematosus and other indications" ”New progress has been made in "going global" research works on traditional Chinese medicine, which have been highly recognized by the World Health Organization and authoritative experts at home and abroad This is another upsurge of artemisinin in the industry since Tu Youyou, a Chinese female scientist, shared the 2015 Nobel Prize in physiology or medicine for her research on artemisinin, an antimalarial drug At the same time, nine artemisinin concept stocks also made a quick response, including Yuheng pharmaceutical, Rundu stock and kunyao group, which took the lead in setting off a round of rising stock tide Three A shares of Fosun Pharmaceutical, Baiyunshan and XinHeCheng have a market value of more than 40 billion Artemisinin "resistance" ushered in new progress The products of 9 listed pharmaceutical companies attracted attention With the news that "Tu youyou and his team have made new breakthroughs in" malaria resistance mechanism research "," drug resistance causes "," adjustment of treatment methods "and other aspects, they have risen to the top of the hot search list Nine artemisinin concept stocks opened higher, and the stock market showed an upward trend At the same time, artemisinin products of 9 listed pharmaceutical companies within the scope of artemisinin concept stocks have also attracted the attention of the industry The screenshot of the picture shows that among the 9 pharmaceutical companies in tonghuashun financial platform, Yuheng Pharmaceutical Co., Ltd., Rundu Stock Co., Ltd and Kunming Pharmaceutical Group Co., Ltd were the top three companies, with Yuheng pharmaceutical leading the way It is reported that astar, a holding company of Yuheng pharmaceutical, is a professional R & D company with strong R & D capabilities Four of astar's patents are related to artemisinin and artemisinin derivatives Rundu shares disclosed in its 2017 annual report that the company's dihydroartemisinin phosphate piperaquine tablet is in the research stage According to the medical intelligence data, the application of "clinical trials of indications of dihydroartemisinin tablets in the treatment of systemic lupus erythematosus and discoid systemic lupus erythematosus" submitted by the Institute of traditional Chinese medicine, Chinese Academy of Chinese medicine, where Tu youyou's team is located, was approved in March 2016 The cooperation between Kunming Pharmaceutical Group and Tu youyou team started in 2016 The former invested 70 million yuan to win the "relevant patents and clinical approvals obtained by the preclinical research institute of dihydroartemisinin tablets new indication - lupus erythematosus research and development project", using milestone payment method At present, the API workshop of the company has successively passed the GMP certification, who certification and FDA certification of TGA in Australia and PMDA in Japan, and the dihydroartemisinin workshop of Wuling pharmaceutical, a subsidiary holding company, has passed who certification, which has advantages in the international supply of antimalarial APIs According to the 2018 annual report, Kunming Pharmaceutical Group's revenue from antimalarial drugs is nearly 70 million yuan, with a corresponding gross margin of more than 50% In addition to the three trading stocks of artemisinin concept stocks, the stock market of six enterprises, such as Fosun Pharmaceutical, Haizheng pharmaceutical and Zhejiang Pharmaceutical, also strengthened Among them, the enterprises that have taken advantage of the relevant approval documents of artemisinin to "get money" include China Resources Shuanghe (dihydroartemisinin preparation), XinHeCheng (artesunate preparation and raw materials, dihydroartemisinin preparation), Baiyunshan (Artemisinin) Haizheng pharmaceutical disclosed in its 2018 annual report that the company has obtained government subsidies for the development of artemisinin efficient synthetic process and related drug industrialization research Artesunate, Guilin south medicine, a subsidiary of Fosun Pharmaceutical, passed the who-pq certification in 2010 Three of the five compounds proposed by who included artesunate In 2014, the sales volume of Fosun artesunate drugs was more than 200 million RMB In addition, according to the 2018 annual report, the company has established a mature drug sales network and upstream and downstream customer resources in French speaking countries and regions in Africa Among them, artemisinin series antimalarial products are highly recognized by the African market, and artesunate for injection is listed as the first choice for severe malaria treatment Zhejiang Pharmaceutical passed the FDA site inspection of the oral solid preparation workshop for the inspection of compound artemether tablets, Xinchang pharmaceutical factory designed the maximum capacity of 200 million tablets / year The compound artemether tablet is a compound preparation of artemether and benflumetol, which is a derivative of artemisinin It is suitable for the treatment of various types of malaria It is reported that a number of artemisinin products under research are on the way in China On April 25, the international academic journal New England Medicine published the title "a temporizing solution to artemisinin" The author is Wang Jigang, a special expert of artemisinin research center and Institute of traditional Chinese medicine of Chinese Academy of Sciences, Dr Chengchao Xu, researcher Liao Fulong, researcher Jiang Tingliang, Professor Sanjeev Krishna and researcher Tu youyou The next generation of antimalarial drugs, which are superior to artemisinins in efficacy, safety and risk of drug resistance, seem unlikely to appear in a short time, the paper said The high cost of drug research and development projects will affect the price of new drugs, and may hinder the most needed patients from obtaining drugs After 40 years of successful development, artemisinin is still the preferred antimalarial drug in combination therapy Therefore, in view of the development prospect of artemisinin, dozens of domestic enterprises have taken the lead According to the data of pharmaceutical intelligence, there are 76 application acceptance numbers of artemisinin, 36 of which are reported for production, 9 for clinical application, and some of them are declared according to the "existing national standards" Among the 36 acceptance numbers reported for production, artemisinin from Chongqing Kerui Nanhai Pharmaceutical Co., Ltd and Hunan Weijia biological Co., Ltd are under review and approval There are also dihydroartemisinin piperaquine of Guilin south medicine, dihydroartemisinin tablets and artesunate tablets of Jiaxing Nanhu pharmaceutical, artesunate tablets of Nanjing Haichen pharmaceutical, and artesunate tablets of Anhui Xinhe and chengwannan pharmaceutical have been approved for clinical use Among the 9 clinical acceptance numbers reported, dihydroartemisinin tablets of Institute of traditional Chinese medicine, Chinese Academy of traditional Chinese medicine, artesunate amodiquine tablets, artesunate amodiquine hydrochloride three-layer tablets and artesunate orally disintegrating tablets of South Guilin medicine have obtained clinical application Information source: Yaozhi data, Xinhuanet, tonghuashun finance and economics, surging news, enterprise announcement and other statements: this point of view only represents the author, not the position of Yaozhi, welcome to exchange and supplement in the message area; if you need to reprint, please be sure to indicate the author and source of the article.